Project Grant HT94252410979
Award Date
8/15/24
Completion Date
8/14/26
Dollars Obligated
$1.9M
Federal Agency
Defense Health Agency
Awardee
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. (UYLKBRENAPG5)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Westlake, MD 20817, USA
Similar Awards
The federal Project Grant award of $1,008,313 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. This award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The award was granted to The Regents of the University of California, San Francisco (UCSF), a prominent academic medical center and research institution, to conduct research on melanoma....
The federal Project Grant award of $3,300,817.00 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research at the Icahn School of Medicine at Mount Sinai (ISMMS) to leverage personalized stem cell therapy and overcome airway reconstruction challenges. This research aims to transform healthcare for military service members, veterans, and the broader public by addressing critical health...
This federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) program, provides $2,985,093.00 to Plus Therapeutics, Inc. (Cytori) to develop a novel targeted radiotherapeutic for the treatment of pediatric high-grade glioma (HGG) and ependymoma. The award period runs from September 1, 2024 to August 31, 2027. The Military Medical Research and Development program supports advanced biomedical research aimed at transforming...
This federal Project Grant award for $1,399,812.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The grant is awarded to the Regents of the University of Minnesota to conduct research on outcomes and late effects in pediatric and adolescent germ cell tumor survivors. This funding will enable...
The federal Project Grant award of $109,632 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program to Radar Therapeutics Inc. in Berkeley, CA. The award, effective August 1, 2025 through July 31, 2026, will support research on the "Selective Translation of LNP-Delivered mRNA for Precision Therapeutics in Rare Cancers including Peripheral T-Cell Lymphoma." This advanced biomedical research aims to transform healthcare for...
The federal Project Grant award, valued at $176,000.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports the Sloan-Kettering Institute for Cancer Research in establishing a mouse model of myxoid/round cell liposarcoma with endogenous translocations. This research aims to transform healthcare for military service members, veterans, and the broader public by advancing biomedical research on critical health...
The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...
The Defense Health Agency awarded a $487,407 Project Grant to Factor Bioscience Inc. under the Military Medical Research and Development (CFDA 12.420) program. The grant, with a performance period from August 1, 2025 to July 31, 2026, supports the development of iPSC-derived mesenchymal stromal cells expressing a novel TNF inhibitor for the treatment of rheumatoid arthritis. This research aims to transform healthcare for military service members, veterans, and the broader public by advancing...
The federal Project Grant award of $624,000.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The award, with a performance period from September 1, 2025, to August 31, 2027, will fund a comprehensive in vivo phenotyping study of fusion-driven pediatric rhabdomyosarcomas conducted by the...
This $626,000 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports Emory University's research on developing immune-competent 3D bioprinted organoids to study and target barriers to cellular therapy for neuroblastoma. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative biomedical solutions. The 2-year award period runs from July 15, 2025 to July...